Ivana K. Kim, M.D.
|Director, Macular Degeneration Unit|
Macular Degeneration Unit
Mass. Eye and Ear
243 Charles Street
Boston, MA 02114
|Office Hours:||Monday afternoons, Wednesday mornings, Thursday afternoons|
|M.D.||Harvard Medical School|
|Residency||Ophthalmology, Harvard Medical School|
|Fellowship||Vitreoretinal Surgery, Mass. Eye and Ear|
|Teaching Affiliation||Associate Professor in Ophthalmology, Harvard Medical School|
Dr. Kim received her medical training at Harvard Medical School. She deepened her knowledge of the eye as a resident in the HMS Department of Ophthalmology Residency Training Program, and subsequently, as a retina fellow at Mass. Eye and Ear.
As a clinician scientist, Dr. Kim investigates genetic risk factors associated with AMD as a means to understand the mechanisms that cause the disease and further refine and advance therapies. In addition, she works to improve visual outcomes in patients with ocular melanoma—investigating strategies to reduce radiation complications—and hopes to help improve survival in these patients by studying frequently occurring mutations in this tumor type.
Her teaching activities involve the medical and surgical training of retina fellows as well as ophthalmology residents. She also mentors medical students and research fellows in the laboratory setting. She is frequently invited to participate in regional and national continuing education courses, such as the annual Macula course, and the American Academy of Ophthalmology Retina Subspecialty Day.
Diseases and surgery of the retina and vitreous, uveal melanoma, age-related macular degeneration, retinal detachment
Age-related macular degeneration, molecular genetics of uveal melanoma
For a full publication list, please see her CV.
Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Yonekawa Y, Andreoli C, Miller JB, Loewenstein JI, Sobrin L, Eliott D, Vavvas DG, Miller JW, Kim IK. Am J Ophthalmol. 2013 Jul;156(1):29-35.e2.
CFH and ARMS2 genetic polymorphisms predict response to antioxidants and zinc in patients with age-related macular degeneration. Awh CC, Lane AM, Hawken S, Zanke B, Kim IK. Ophthalmology. 2013 Nov;120(11):2317-23.
Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT) . Hagstrom SA, Ying GS, Pauer GJ, Sturgill-Short GM, Huang J, Callanan DG, Kim IK, Klein ML, Maguire MG, Martin DF; Comparison of AMD Treatments Trials Research Group. Ophthalmology. 2013 Mar;120(3):593-9.
High throughput mass spectrometry-based mutation profiling of primary uveal melanoma. Daniels AB, Lee JE, Macconaill LE, Palescandolo E, Van Hummelen P, Adams SM, Deangelis MM, Hahn WC, Gragoudas ES, Harbour JW, Garraway LA, Kim IK. Invest Ophthalmol Vis Sci. 2012 Oct 9;53(11):6991-6.
Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. Njauw CN, Kim I, Piris A, Gabree M, Taylor M, Lane AM, Deangelis MM, Gragoudas E, Duncan LM, Tsao H. PLoS One. 2012;7(4):e35295.
To learn more about Dr. Kim, click here to read her “Meet a Specialist” profile.